Literature DB >> 29255148

Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis.

Wenjie Guo1, Wen Liu1, Zhen Chen2, Yanhong Gu3, Shuang Peng1, Lihong Shen1, Yan Shen1, Xingqi Wang1, Gen-Sheng Feng4, Yang Sun5, Qiang Xu6.   

Abstract

Aberrant activation of NLRP3 inflammasome has an important function in the pathogenesis of various inflammatory diseases. Although many components and mediators of inflammasome activation have been identified, how NLRP3 inflammasome is regulated to prevent excessive inflammation is unclear. Here we show NLRP3 inflammasome stimulators trigger Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) translocation to the mitochondria, to interact with and dephosphorylate adenine nucleotide translocase 1 (ANT1), a central molecule controlling mitochondrial permeability transition. This mechanism prevents collapse of mitochondrial membrane potential and the subsequent release of mitochondrial DNA and reactive oxygen species, thus preventing hyperactivation of NLRP3 inflammasome. Ablation or inhibition of SHP2 in macrophages causes intensified NLRP3 activation, overproduction of proinflammatory cytokines IL-1β and IL-18, and increased sensitivity to peritonitis. Collectively, our data highlight that, by inhibiting ANT1 and mitochondrial dysfunction, SHP2 orchestrates an intrinsic regulatory loop to limit excessive NLRP3 inflammasome activation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29255148      PMCID: PMC5735095          DOI: 10.1038/s41467-017-02351-0

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  47 in total

1.  Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.

Authors:  Audrey De Rocca Serra-Nédélec; Thomas Edouard; Karine Tréguer; Mylène Tajan; Toshiyuki Araki; Marie Dance; Marianne Mus; Alexandra Montagner; Maïté Tauber; Jean-Pierre Salles; Philippe Valet; Benjamin G Neel; Patrick Raynal; Armelle Yart
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

2.  Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription.

Authors:  Wanwan Huai; Rui Zhao; Hui Song; Jing Zhao; Lei Zhang; Lining Zhang; Chengjiang Gao; Lihui Han; Wei Zhao
Journal:  Nat Commun       Date:  2014-08-20       Impact factor: 14.919

3.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

4.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  Tyrosine phosphorylation by Src within the cavity of the adenine nucleotide translocase 1 regulates ADP/ATP exchange in mitochondria.

Authors:  Jianhua Feng; Eliana Lucchinetti; Giray Enkavi; Yi Wang; Peter Gehrig; Bernd Roschitzki; Marcus C Schaub; Emad Tajkhorshid; Kathrin Zaugg; Michael Zaugg
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-09       Impact factor: 4.249

6.  Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor.

Authors:  Yuan Ren; Songshu Meng; Lin Mei; Z Joe Zhao; Richard Jove; Jie Wu
Journal:  J Biol Chem       Date:  2003-12-08       Impact factor: 5.157

7.  Localization of PTP-1B, SHP-2, and Src exclusively in rat brain mitochondria and functional consequences.

Authors:  Amal Arachiche; Olivier Augereau; Marion Decossas; Claire Pertuiset; Etienne Gontier; Thierry Letellier; Jeanne Dachary-Prigent
Journal:  J Biol Chem       Date:  2008-06-26       Impact factor: 5.157

8.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

9.  Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL.

Authors:  Seok Min Jin; Michael Lazarou; Chunxin Wang; Lesley A Kane; Derek P Narendra; Richard J Youle
Journal:  J Cell Biol       Date:  2010-11-29       Impact factor: 10.539

10.  LRRFIP2 negatively regulates NLRP3 inflammasome activation in macrophages by promoting Flightless-I-mediated caspase-1 inhibition.

Authors:  Jing Jin; Qian Yu; Chaofeng Han; Xiang Hu; Sheng Xu; Qingqing Wang; Jianli Wang; Nan Li; Xuetao Cao
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  31 in total

1.  Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome.

Authors:  Wen Yu; Guangjun Jin; Jiancheng Zhang; Wei Wei
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  Tumor-associated macrophages (TAMs) depend on Shp2 for their anti-tumor roles in colorectal cancer.

Authors:  Saisai Wang; Yuanyuan Yao; Huixia Li; Gang Zheng; Sen Lu; Wenbin Chen
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

3.  Crosstalk Between RPE Cells and Choroidal Endothelial Cells via the ANXA1/FPR2/SHP2/NLRP3 Inflammasome/Pyroptosis Axis Promotes Choroidal Neovascularization.

Authors:  Manhui Zhu; Ying Wang; Linling Zhu; Shu Du; Zhenzhen Wang; Yuting Zhang; Yang Guo; Yuanyuan Tu; E Song
Journal:  Inflammation       Date:  2021-10-01       Impact factor: 4.092

4.  CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.

Authors:  Joseph Farahany; Yoshikazu Tsukasaki; Amitabha Mukhopadhyay; Manish Mittal; Saroj Nepal; Chinnaswamy Tiruppathi; Asrar B Malik
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 6.914

5.  SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1.

Authors:  Appolinaire A Olou; Joe Ambrose; Jarrid L Jack; McKinnon Walsh; Mariana T Ruckert; Austin E Eades; Bailey A Bye; Prasad Dandawate; Michael N VanSaun
Journal:  J Cell Commun Signal       Date:  2022-09-08       Impact factor: 5.908

6.  Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling.

Authors:  Ziying Sun; Qianqian Liu; Zhongyang Lv; Jiawei Li; Xingquan Xu; Heng Sun; Maochun Wang; Kuoyang Sun; Tianshu Shi; Zizheng Liu; Guihua Tan; Wenqiang Yan; Rui Wu; Yannick Xiaofan Yang; Shiro Ikegawa; Qing Jiang; Yang Sun; Dongquan Shi
Journal:  Acta Pharm Sin B       Date:  2022-02-17       Impact factor: 14.903

7.  Disrupting phosphatase SHP2 in macrophages protects mice from high-fat diet-induced hepatic steatosis and insulin resistance by elevating IL-18 levels.

Authors:  Wen Liu; Ye Yin; Meijing Wang; Ting Fan; Yuyu Zhu; Lihong Shen; Shuang Peng; Jian Gao; Guoliang Deng; Xiangbao Meng; Lingdong Kong; Gen-Sheng Feng; Wenjie Guo; Qiang Xu; Yang Sun
Journal:  J Biol Chem       Date:  2020-06-16       Impact factor: 5.157

8.  Butorphanol Promotes Macrophage Phenotypic Transition to Inhibit Inflammatory Lung Injury via κ Receptors.

Authors:  Guangxin Luan; Fan Pan; Lina Bu; Kaixuan Wu; Aizhong Wang; Xiaotao Xu
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

9.  Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.

Authors:  Javier-Fernando Montero-Bullón; Óscar González-Velasco; María Isidoro-García; Jesus Lacal
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

Review 10.  The Role of Protein Tyrosine Phosphatases in Inflammasome Activation.

Authors:  Marianne R Spalinger; Marlene Schwarzfischer; Michael Scharl
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.